Table 2. Number of pathogenic CNVs in ID and ASD patients with each clinical features.
| Clinical features | Pathogenic CNVs in ID group N = 90 | Pathogenic CNVs in ASD group N = 114 | Pathogenic CNVs in both groups |
|---|---|---|---|
| ADHD (N = 60) | 17.65% (3/17) | 9.30% (4/43) | 11.67% (7/60) |
| Epilepsy (N = 22) | 21.43% (3/14) | 37.50% (3/8) | 27.27% (6/22) |
| Microcephaly (N = 23) | 38.89% (7/18) | 0.00% (0/5) | 30.43% (7/23) |
| Macrocephaly (N = 11) | 0.00% (0/7) | 0.25% (1/4) | 9.09% (1/11) |
| Dysmorphic features (N = 43) | 37.93% (11/29) | 28.57% (4/14) | 34.88% (15/43) |
| Developmental defectsa (N = 28) | 11.11% (2/18) | 0.00% (0/10) | 7.14% (2/28) |
| Growth defects (N = 16) | 30.00% (3/10) | 0.00% (0/6) | 18.75% (3/16) |
Notes.
a
Heart, urogenital and brain; ADHD, hyperactivity; ID, intellectual disabilities patients; ASD, autism spectrum disorders patients; CNVs, copy number variants.